Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ZILBRYSQ safely and effectively. See full prescribing information for ZILBRYSQ. ZILBRYSQ (zilucoplan) injection, for subcutaneous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
- generic_name
- zilucoplan
- product_names
- zilucoplan
- ndc
- 50474-990, 50474-990-80, 50474-991, 50474-991-80, 50474-992, 50474-992-80
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en